Physician profile
Eric T Lao
NPI 1801878681
$9,649.38
in general payments reported to CMS, 2019-2025
42 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.54 · 2020: $44.85 · 2021: $1,186 · 2022: $1,856 · 2023: $2,547 · 2024: $2,442 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,506 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,505.83 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,710.95 | 2021-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $1,226.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,132.76 | 2021-2025 | Mounjaro, Zepbound, Lyumjev |
| Abbvie INC. | $709.47 | 2021-2025 | |
| Glaxosmithkline, LLC. | $690.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $455.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.44 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $313.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $291.06 | 2021-2024 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $264.47 | 2022-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.34 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $232.41 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $204.39 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $187.41 | 2023-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $171.44 | 2024-2025 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.